Geneo Clarify: What Clinics Should Know About the New GeneoX Treatment

Discover what changes as Geneo Clarify replaces Balance. Watch DermaSpark’s webinar for the OxyPod and serum ingredient breakdown, reported findings and patient-selection considerations.
November 11, 2026
2–3 minutes

Geneo® Clarify is a GeneoX treatment designed for oily, congested, and acne-prone skin. It replaces Balance with a reformulated OxyPod and serum, bringing together ingredients selected for purification, exfoliation, and hydration.

In this DermaSpark webinar, Clinical Director Doron Heichal explains what has changed and how clinics can assess its place in their treatment menu. Following DermaSpark’s announcement of Clarify’s Cosmopolitan recognition, this session takes a closer look at the formulation and practical considerations.

Watch the Geneo Clarify webinar

Watch the approximately 57-minute presentation for the ingredient breakdown, comparison with Balance and patient-selection discussion.

Watch on YouTube · Balance comparison: 42:03 · Patient suitability: 48:04

How is Geneo Clarify different from Balance?

The intended skin concerns remain similar, but both parts of the treatment have changed. Doron Heichal highlights spherical activated bamboo charcoal particles in the Clarify OxyPod and a revised blend of exfoliating and botanical ingredients.

The serum also has a new formulation. Its inclusion of mango butter, Aquaxyl and glycerin reflects a central theme of the webinar: addressing oiliness while supporting hydration and skin comfort.

Which ingredients does the webinar cover?

  • Geneo Clarify OxyPod: activated bamboo charcoal beads, salicylate ingredients, lilac extract, lactic acid, and Lactobacillus-related ingredients.
  • Geneo Clarify serum: salicylic acid, wasabi and harungana extracts, plus mango butter, Aquaxyl and glycerin.

Doron Heichal explains the rationale for each group, from exfoliation and oil control to hydration. For broader platform information, explore DermaSpark’s GeneoX and OxyGeneo Super Facial page.

What do the reported results mean?

At approximately 39:30, Doron describes Pollogen laboratory testing reporting a 99% reduction in C. acnes bacteria within 10 minutes and a 97% reduction in the tested yeast. These are laboratory findings, not percentages of acne clearance in patients.

He separately reports a 15% decrease in sebum production after three treatments in a preliminary clinical investigation that was ongoing at the time of recording. The webinar does not provide enough study detail to predict individual outcomes.

Who may be suitable for Geneo Clarify?

The webinar focuses on oiliness, congestion, blackheads and whiteheads, and discusses selected mild-to-moderate acne cases following professional assessment. Doron advises against treating severe, highly inflamed acne with Clarify.

Clinics should follow current manufacturer protocols and assess skin condition, medications and contraindications. Severe or persistent acne warrants medical assessment; the American Academy of Dermatology explains the role of dermatological treatment.

Frequently asked questions

Does Geneo Clarify replace Balance?

Yes. Doron introduces Clarify as the replacement for Balance, with updated OxyPod and serum formulations.

Is Geneo Clarify a standalone machine?

No. It is a targeted OxyPod and serum treatment within the Geneo offering. Ask DermaSpark to confirm compatibility with your clinic’s equipment.

How many sessions are needed?

The webinar does not establish one schedule for every patient. Plan treatment and review points according to assessment, current protocols and response.

Explore Geneo Clarify for your clinic

Already offering OxyGeneo? Ask about transitioning from Balance and updating your team’s training. Considering the platform? Contact DermaSpark for a demonstration and guidance on Geneo Clarify.

Based on DermaSpark’s Geneo Clarify webinar. Ingredient rationale and study figures are attributed to the presenter. This summary complements professional training; treatment suitability and outcomes vary.

Doron Heichal

Clinical Director, DermaSpark
Biomedical Engineer
Doron Heichal is Clinical Director at DermaSpark and a Biomedical Engineer specializing in evidence-based medical aesthetics, protocols, and clinical education to help Canadian clinics deliver safe, predictable patient outcomes.
View author profile on LinkedIn
Evaluating a Device for your clinic?
Speak with a DermaSpark specialist about equipment, treatment goals and business fit.
Contact us
Stay Informed
Clinical insights, new technologies and clinic growth ideas.
Receive selected DermaSpark articles and industry updates in your inbox.
Book a Demo